Table 3.
Proteomics-Based Analysis of Biomarkers From Plasma-Derived Extracellular Vesicles in Patients With Glioma
| Biomarker | Method | Study |
|---|---|---|
| Syndecan-1 (SDC1), 12 proteins differed in HGG vs LGG |
Liquid chromatography-mass spectrometry (LC-MS)) Ultrasensitive proximity extension immunoassay (PEA) Enzymelinked immunosorbent assay (ELISA) |
Chandran et al41 |
| Tropomyosin kinase receptor (TrkB) | Western blot | Pinet et al39 |
| GFAP, TAU | Dielectrophoresis(DEP) Immunofluorescence staining (IF) | Lewis et al42 |
| INFγ, IL-10, IL-13, CD80, CD86, B7-1, B7-2, flotillin-1, ICOSL |
Cytokine and checkpoint molecules arrays Western blot ELISA |
Cumba Garcia et al15 |
| 11 differentially expressed proteins |
Sequential window acquisition of all theoretical fragment ion spectra mass spectrometry (SWATH-MS) LC-MS |
Hallal et al43 |
| von Willebrand factor (VWF) | LC-MS | Sabbagh et al44 |
| VWF, APCS, C4B, AMBP, APOD, AZGP1, C4BPB, Serpin3, FTL, C3, and APOE | Liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) | Osti et al16 |
| Fatty acid synthase (FASN) |
Western blot Imaging flow cytometry (IFCM) |
Ricklefs et al45 |